Physician
Emergency Medicine
Dr. Richard L. Kendall, MD
|
|
Give Review
Richard Kendall works in the field of Emergency Medicine. He graduated from The Ohio State University College of Medicine. Doctor Richard L. Kendall, MD has written publications. He has 42 publications published with PubMed. The lastest paper is: 'Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.'
Publications
- Discovery of 1H-Pyrazol-3(2H)-ones as Potent and Selective Inhibitors of Protein Kinase R-like Endoplasmic Reticulum Kinase (PERK).
- The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.
- Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability.
- Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method.
- AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models.
- Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab.
- Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
- Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
- Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor.
- Kinetic mechanism of AKT/PKB enzyme family.
- AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.
- IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
- Isolation and characterization of the methionine aminopeptidase from porcine liver responsible for the co-translational processing of proteins.
- Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes.
- Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.
- N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists.
- Specificity of vascular endothelial cell growth factor receptor ligand binding domains.
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.
- Discovery of a small molecule insulin mimetic with antidiabetic activity in mice.
- Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.
- Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
- Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
- Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
- Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
- Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth fa...
- AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xeno...
- Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr.
- Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase.
- Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
- Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues.
- AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibi...
- Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
- Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing pep...
- Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth.
- Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
- AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
- The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
- Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.
- Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR.
- Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.
- Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors.
Schools
Ohio State University College of Medicine
St Vincent Med Center
Doctors Specialties
- Emergency Medicine
Accepted Insurances
Education
-
The Ohio State University College of Medicine
Drug Facts
| NPI NUMBER | 1285648097 | |
| NPPES Provider LastName | KENDALL | |
| NPPES Provider FirstName | RICHARD | |
| NPPES Provider ZIPCode | 434521010 | |
| NPPES Provider State | OH | |
| Specialty Description | General Practice | |
| Total Claim Count | 552.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 83.0 | |
| Percent Opioid Claims | 15.04 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285648097 |
| Last Name Of The Provider | KENDALL |
| First Name Of The Provider | RICHARD |
| View All |
Similar Doctors
|
|
Dr. Marvin D. Stalter, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott D. Zgrabik, MD
This Doctor is OpenDoctor Recommended.
|